Semaglutide [Peptide]

Description

Semaglutide [Peptide]

The product is only intended for laboratory research use and not for human consumption. 

Available quantities:

• 5 mg
• 10 mg

Product Information 

Molecular Sequence of Semaglutide Peptide 

H–His–Aib–Glu–Gly–Thr–Phe–Thr–Ser–Asp–Val–Ser–Ser–Tyr–Leu–Glu–Gly–Gln–Ala–Ala–Lys{γ-Glu–AEEA(2×OEG)–C18-diacid}–Glu–Phe–Ile–Ala–Trp–Leu–Val–Arg–Gly–Arg–Gly–OH ® 

• Aib = α-Aminoisobutyric acid
• γ-Glu = γ-Glutamic acid (used as a linker).
• AEEA (2×OEG) = aminoethoxyethoxyacetic acid (short PEG-like spacer, sometimes shown as 2×OEG or AEEA).
• C18-diacid = an octadecanedioic (C18) fatty diacid attached to the ε-amine of the Lys residue ®

Handling and Storage of Semaglutide Peptide 

The peptide compound should be stored in a cool and dry place to maximize its stability. For better storage, it is recommended to keep the Semaglutide lyophilized peptides refrigerated between 2°C and 8°C (36°F–46°F) in an air-sealed container. ®

Overview of the Semaglutide

Semaglutide is a synthetically derived peptide. It belongs to a class of glucagon-like peptide-1 (GLP-1) receptor agonists. It is a laboratory-made compound, designed to mimic the mechanism of naturally occurring peptide GLP-1. ® 

In laboratories, semaglutide is based on a 31-amino-acid sequence with the addition of a C-18 fatty acid chain and is approximately 94% homologous to the endogenous GLP-1 peptide. Additionally, it is formulated to resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) in experimental models. ®

Working Mechanism of the Peptide

• The formulation properties of Wegovy and Ozempic (Semaglutide) make it valuable for laboratory researchers to study its potential role in controlling blood sugar levels, hunger control, and weight management in laboratory models. ®
• Research suggests that the compound stimulates GLP-1 receptors on beta cells to release insulin in research models. ® 
• In laboratory settings, semaglutide has been shown to activate GLP-1 receptors in the hypothalamus, which controls hunger and appetite pathways in experimental models.®  Preclinical studies suggest semaglutide may influence inflammation markers, lipid metabolism, and cardiovascular function. ®

Besides potential mechanisms, here are some common side effects of the compound observed in different research models:

• Nausea 
• Fatigue
• Dizziness
• Headache

TFA Salt Form 

Semaglutide is provided in its TFA salt form. Residual trifluoroacetate content is typically up to 10% w/w. It depends on the final formulation and lyophilization conditions. The exact TFA content can be confirmed by batch-specific COA.

Disclaimer

Semaglutide peptide is intended exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, treat, cure, or prevent any disease. The Food and Drug Administration has not evaluated the statements on our website. By purchasing, you agree to our Terms and Conditions.

For queries, complaints, or support, please contact support@rcdbio.co.